Search - tctmd.com

Displaying 781 - 800 of 1817

Sort: Relevancy | Date

Presentation TCT 2019

Alcohol-Mediated Renal Denervation: 1-Year and Final Results From the Peregrine Postmarket Study

Presenter: Felix Mahfoud

September 27, 2019

Presentation TCT 2019

The Target BP Program: Ongoing and Future Studies

Presenter: David Kandzari

September 27, 2019

Presentation TCT 2019

Complex Aortoiliac Occlusive Disease: Achieving Differentiated Performance Through Advanced Technology

Presenter: Ehrin Armstrong

September 27, 2019

Presentation TCT 2019

Clinical Evaluation: Peregrine Results to Date

Presenter: Felix Mahfoud

September 27, 2019

Presentation TCT 2019

Procedure Overview: Alcohol-mediated RDN Using the Peregrine System

Presenter: Horst Sievert

September 27, 2019

Presentation TCT 2019

Alcohol-Mediated Renal Denervation: How is it Different?

Presenter: Melvin Lobo

September 27, 2019

Presentation TCT 2019

Case 3: Interventional Treatment of Acute Pulmonary Emboli

Presenter: Gregory Piazza

September 26, 2019

Presentation TCT 2019

Case 2: Interventional Treatment of Acute Pulmonary Emboli

Presenter: Andrew Klein

September 26, 2019

Presentation TCT 2019

Case 1: Interventional Treatment of Acute Pulmonary Emboli

Presenter: Philip Green

September 26, 2019

Presentation TCT 2019

Utility and Risks of Vena Cava Filters to Prevent PE

Presenter: Riyaz Bashir

September 26, 2019

Presentation TCT 2019

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Presenter: Rebecca Ward

September 26, 2019

Presentation TCT 2019

Catheter-Directed Therapy for Acute PE II: Indications, Options, Outcomes

Presenter: Thomas Tu

September 26, 2019

Presentation TCT 2019

Potential Study Designs to Address the Mortality Safety Signal

Presenter: Laura Mauri

September 26, 2019

Presentation TCT 2019

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Systemic Therapy for Acute PE: Options, Effectiveness, Safety

Presenter: Jay Giri

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

PERT: Why and How

Presenter: Robert Lookstein

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Advertisement

Alcohol-Mediated Renal Denervation: 1-Year and Final Results From the Peregrine Postmarket Study

The Target BP Program: Ongoing and Future Studies

Complex Aortoiliac Occlusive Disease: Achieving Differentiated Performance Through Advanced Technology

Clinical Evaluation: Peregrine Results to Date

Procedure Overview: Alcohol-mediated RDN Using the Peregrine System

Alcohol-Mediated Renal Denervation: How is it Different?

Case 3: Interventional Treatment of Acute Pulmonary Emboli

Case 2: Interventional Treatment of Acute Pulmonary Emboli

Case 1: Interventional Treatment of Acute Pulmonary Emboli

Utility and Risks of Vena Cava Filters to Prevent PE

Emerging Safety Signals and FDA’s Medical Device Safety Action Plan: Responses to the Late Mortality Signal

Catheter-Directed Therapy for Acute PE II: Indications, Options, Outcomes

Potential Study Designs to Address the Mortality Safety Signal

Informed Consent and Impact on Clinical Practice: A Clinician’s Perspective and a Pathway Forward

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Systemic Therapy for Acute PE: Options, Effectiveness, Safety

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

PERT: Why and How

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content